Vanguard Group Inc Genprex, Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$1.0 - $58.8 $1,043 - $61,328	1,043 Added 0.06%	1,826,600 $2.65 Million
Q3 2022 Nov 14, 2022	BUY	$1.32 - $58.0 $821 - $36,076	622 Added 0.03%	1,825,557 $2.57 Million
Q2 2022 Aug 12, 2022	BUY	$1.28 - $2.31 $16,304 - $29,424	12,738 Added 0.7%	1,824,935 $2.54 Million
Q1 2022 May 13, 2022	SELL	$1.82 - $3.5 $54,396 - $104,608	-29,888 Reduced 1.62%	1,812,197 $4.1 Million
Q4 2021 Feb 14, 2022	SELL	$1.21 - $2.7 $11,793 - $26,316	-9,747 Reduced 0.53%	1,842,085 $2.41 Million
Q2 2021 Aug 13, 2021	BUY	$3.11 - $4.87 $5.76 Million - $9.02 Million	1,851,832 New	1,851,832 $6.2 Million

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $39.9M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.